Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ

Stock Track

02-24

Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.

The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.

Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1117228916"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117228916\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1117228916?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117228916","market":"hk","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ","media":"Stock Track","content":"<p>Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.</p>\n\n<p>The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.</p>\n\n<p>Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-24 21:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.</p>\n\n<p>The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.</p>\n\n<p>Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1117228916","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117228916","pubTimestamp":1740404546,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Myriad Genetics  shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Myriad Genetics因与PATHOMIQ达成许可协议而盘前暴跌6.56%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.\nThe deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.\nMyriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}